SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-068440
Filing Date
2021-03-04
Accepted
2021-03-04 07:05:28
Documents
4
Period of Report
2021-02-26
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d122679d8k.htm 8-K 30931
2 EX-99.1 d122679dex991.htm EX-99.1 69741
3 EX-99.2 d122679dex992.htm EX-99.2 9371
4 GRAPHIC g122679g0304030524751.jpg GRAPHIC 3788
  Complete submission text file 0001193125-21-068440.txt   116686
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

IRS No.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38978 | Film No.: 21712542
SIC: 2834 Pharmaceutical Preparations